middle.news
How Alterity’s ATH434 Is Slowing Multiple System Atrophy Progression
11:21am on Monday 15th of September, 2025 AEST
•
Biotechnology
Read Story
How Alterity’s ATH434 Is Slowing Multiple System Atrophy Progression
11:21am on Monday 15th of September, 2025 AEST
Key Points
ATH434 significantly slowed disease progression in MSA patients
Both 50 mg and 75 mg doses showed clinical efficacy and good tolerability
Biomarker data confirmed reduction of iron accumulation in affected brain regions
Trial employed wearable sensors to assess motor activity outside clinical settings
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE